PubMed:33125711
Annnotations
LitCovid_Glycan-Motif-Structure
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 15-22 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T2 | 15-22 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T3 | 238-245 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | Heparin |
T4 | 238-245 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | Heparin |
T5 | 415-422 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T6 | 415-422 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T7 | 563-570 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T8 | 563-570 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T9 | 674-681 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T10 | 674-681 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T11 | 734-742 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparins |
T12 | 734-742 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparins |
T13 | 929-936 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T14 | 929-936 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T15 | 1331-1338 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T16 | 1331-1338 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T17 | 1403-1410 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
T18 | 1403-1410 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
T19 | 1553-1561 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparins |
T20 | 1553-1561 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparins |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 15-22 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T2 | 58-62 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T3 | 238-245 | Body_part | denotes | Heparin | http://purl.org/sig/ont/fma/fma82839 |
T4 | 415-422 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T5 | 563-570 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T6 | 674-681 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T7 | 734-742 | Body_part | denotes | heparins | http://purl.org/sig/ont/fma/fma82839 |
T8 | 907-912 | Body_part | denotes | cells | http://purl.org/sig/ont/fma/fma68646 |
T9 | 929-936 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T10 | 948-955 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T11 | 1061-1068 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T12 | 1331-1338 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T13 | 1370-1377 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T14 | 1403-1410 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
T15 | 1466-1473 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T16 | 1553-1561 | Body_part | denotes | heparins | http://purl.org/sig/ont/fma/fma82839 |
T17 | 1694-1701 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T18 | 1720-1727 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T1 | 47-55 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T2 | 228-236 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T3 | 325-333 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T4 | 450-458 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
T5 | 602-610 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T6 | 828-836 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T7 | 1599-1607 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T8 | 1853-1861 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 58-62 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
T2 | 471-472 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T3 | 494-495 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
T4 | 806-814 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T5 | 868-869 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T6 | 899-912 | http://purl.obolibrary.org/obo/CLO_0051719 | denotes | Vero E6 cells |
T7 | 1050-1055 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T8 | 1206-1208 | http://purl.obolibrary.org/obo/CLO_0053794 | denotes | 41 |
T9 | 1212-1216 | http://purl.obolibrary.org/obo/CLO_0007735 | denotes | ml-1 |
T10 | 1290-1294 | http://purl.obolibrary.org/obo/CLO_0007735 | denotes | ml-1 |
T11 | 1455-1460 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T12 | 1572-1575 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
T13 | 1620-1628 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
T14 | 1709-1714 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
T15 | 1813-1814 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T1 | 15-22 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T2 | 196-206 | Chemical | denotes | antivirals | http://purl.obolibrary.org/obo/CHEBI_22587 |
T3 | 238-245 | Chemical | denotes | Heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T4 | 298-311 | Chemical | denotes | anticoagulant | http://purl.obolibrary.org/obo/CHEBI_50249 |
T5 | 415-422 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T6 | 535-544 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T7 | 563-570 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T8 | 674-681 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T9 | 734-742 | Chemical | denotes | heparins | http://purl.obolibrary.org/obo/CHEBI_24505 |
T10 | 796-805 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T11 | 929-936 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T12 | 948-955 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T13 | 1061-1068 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T14 | 1151-1160 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T15 | 1331-1338 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T16 | 1370-1377 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T17 | 1403-1410 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
T18 | 1466-1473 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T19 | 1553-1561 | Chemical | denotes | heparins | http://purl.obolibrary.org/obo/CHEBI_24505 |
T20 | 1610-1619 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
T21 | 1694-1701 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
T22 | 1720-1727 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 1669-1684 | http://purl.obolibrary.org/obo/GO_0051100 | denotes | inhibit binding |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
2 | 15-22 | Chemical | denotes | heparin | MESH:D006493 |
3 | 47-57 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
38 | 228-236 | Disease | denotes | COVID-19 | MESH:C000657245 |
39 | 238-245 | Chemical | denotes | Heparin | MESH:D006493 |
40 | 325-333 | Disease | denotes | COVID-19 | MESH:C000657245 |
41 | 334-342 | Species | denotes | patients | Tax:9606 |
42 | 415-422 | Chemical | denotes | heparin | MESH:D006493 |
43 | 424-427 | Chemical | denotes | UFH | MESH:D006493 |
44 | 450-458 | Disease | denotes | COVID-19 | MESH:C000657245 |
45 | 459-467 | Species | denotes | patients | Tax:9606 |
46 | 563-570 | Chemical | denotes | heparin | MESH:D006493 |
47 | 602-612 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
48 | 674-681 | Chemical | denotes | heparin | MESH:D006493 |
49 | 705-708 | Chemical | denotes | UFH | MESH:D006493 |
50 | 713-742 | Chemical | denotes | low molecular weight heparins | MESH:D006495 |
51 | 764-770 | Species | denotes | bovine | Tax:9913 |
52 | 828-838 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
53 | 929-936 | Chemical | denotes | heparin | MESH:D006493 |
54 | 1050-1055 | Species | denotes | human | Tax:9606 |
55 | 1056-1060 | Gene | denotes | ACE2 | Gene:59272 |
56 | 1123-1126 | Chemical | denotes | UFH | MESH:D006493 |
57 | 1212-1216 | Gene | denotes | ml-1 | Gene:112744 |
58 | 1290-1294 | Gene | denotes | ml-1 | Gene:112744 |
59 | 1331-1338 | Chemical | denotes | heparin | MESH:D006493 |
60 | 1403-1410 | Chemical | denotes | heparin | MESH:D006493 |
61 | 1455-1460 | Species | denotes | human | Tax:9606 |
62 | 1461-1465 | Gene | denotes | ACE2 | Gene:59272 |
63 | 1553-1561 | Chemical | denotes | heparins | MESH:D006493 |
64 | 1568-1571 | Chemical | denotes | UFH | MESH:D006493 |
65 | 1599-1609 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
66 | 1648-1651 | Chemical | denotes | UFH | MESH:D006493 |
67 | 1709-1714 | Species | denotes | human | Tax:9606 |
68 | 1715-1719 | Gene | denotes | ACE2 | Gene:59272 |
69 | 1806-1809 | Chemical | denotes | UFH | MESH:D006493 |
70 | 1839-1847 | Species | denotes | patients | Tax:9606 |
71 | 1853-1861 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 0-118 | Sentence | denotes | Unfractionated heparin inhibits live wild-type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations. |
T2 | 119-142 | Sentence | denotes | BACKGROUND AND PURPOSE: |
T3 | 143-237 | Sentence | denotes | Currently there are no licensed vaccines and limited antivirals for the treatment of COVID-19. |
T4 | 238-343 | Sentence | denotes | Heparin (delivered systemically) is currently used to treat anticoagulant anomalies in COVID-19 patients. |
T5 | 344-493 | Sentence | denotes | In addition, in the UK, Brazil and Australia, nebulised unfractionated heparin (UFH) is being trialled in COVID-19 patients as a potential treatment. |
T6 | 494-634 | Sentence | denotes | A systematic comparison of the potential antiviral effect of various heparin preparations on live wild-type SARS-CoV-2, in vitro, is needed. |
T7 | 635-657 | Sentence | denotes | EXPERIMENTAL APPROACH: |
T8 | 658-913 | Sentence | denotes | Seven different heparin preparations including UFH and low molecular weight heparins (LMWH) of porcine or bovine origin were screened for antiviral activity against live SARS-CoV-2 (Australia/VIC01/2020) using a plaque inhibition assay with Vero E6 cells. |
T9 | 914-1101 | Sentence | denotes | Interaction of heparin with spike protein RBD was studied using differential scanning fluorimetry, and the inhibition of RBD binding to human ACE2 protein using ELISA assays was examined. |
T10 | 1102-1114 | Sentence | denotes | KEY RESULTS: |
T11 | 1115-1297 | Sentence | denotes | All the UFH preparations had potent antiviral effects, with IC50 values ranging between 25-41 μg ml-1 whereas LMWHs were less inhibitory by ~150-fold (IC50 range 3.4 - 7.8 mg ml-1 ). |
T12 | 1298-1483 | Sentence | denotes | Mechanistically we observed that heparin binds and destabilizes the RBD protein, and furthermore we show heparin directly inhibits the binding of RBD to the human ACE2 protein receptor. |
T13 | 1484-1513 | Sentence | denotes | CONCLUSIONS AND IMPLICATIONS: |
T14 | 1514-1647 | Sentence | denotes | This comparison of clinically relevant heparins shows UFH has significantly stronger SARS-CoV-2 antiviral activity compared to LMWHs. |
T15 | 1648-1737 | Sentence | denotes | UFH acts to directly inhibit binding of spike protein to the human ACE2 protein receptor. |
T16 | 1738-1862 | Sentence | denotes | Overall the data strongly support further clinical investigation of UFH as a potential treatment for patients with COVID-19. |